Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/8414
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLosen, M-
dc.contributor.authorMartinez-Martinez, Pilar-
dc.contributor.authorPhernambucq, M-
dc.contributor.authorSchuurman, J-
dc.contributor.authorParren, PWWI-
dc.contributor.authorDE BAETS, Marc-
dc.date.accessioned2008-07-28T13:55:47Z-
dc.date.available2008-07-28T13:55:47Z-
dc.date.issued2008-
dc.identifier.citationKaminski, HJ & Barohn, RJ (Ed.) MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE. p. 174-179.-
dc.identifier.isbn978-1-57331-687-3-
dc.identifier.issn0077-8923-
dc.identifier.urihttp://hdl.handle.net/1942/8414-
dc.description.abstractMyasthenia gravis (MG) is an autoimmune disease caused by antibodies mainly directed to the acetylcholine receptor (AChR) of the neuromuscular junction. Induction of antigenic modulation and complement activation by such autoantibodies leads to ultrastructural damage of the postsynaptic membrane and loss of AChR and associated proteins. Reduction of antigenic modulation by increasing the expression of the receptor-associated anchor protein, rapsyn, or by functionally monovalent competing IgG4 anti-AChR antibodies was shown to prevent MG disease activity. We propose that preventing antigenic modulation can be used as a treatment strategy for MG.-
dc.language.isoen-
dc.publisherBLACKWELL PUBLISHING-
dc.relation.ispartofseriesANNALS OF THE NEW YORK ACADEMY OF SCIENCES-
dc.subject.otherrapsyn, IgG4, antigenic modulation, complement-
dc.titleTreatment of myasthenia gravis by preventing acetylcholine receptor modulation-
dc.typeProceedings Paper-
local.bibliographicCitation.authorsKaminski, HJ-
local.bibliographicCitation.authorsBarohn, RJ-
local.bibliographicCitation.conferencedateMAY, 2007-
local.bibliographicCitation.conferencenameInternational Conference on Myasthenia Gravis and Related Disorder-
dc.bibliographicCitation.conferencenr11-
local.bibliographicCitation.conferenceplaceChicago, IL,-
dc.identifier.epage179-
dc.identifier.issueMyasthenia Gravis and Related Disorders 11th International Conference-
dc.identifier.spage174-
dc.identifier.volume1132-
local.format.pages6-
local.bibliographicCitation.jcatC1-
dc.description.notesUniv Maastricht, Neuroimmunol Grp, Inst Mental Hlth & Neurosci,Dept Neurosci, Netherlands European Grad Sch Neuro EURON, Maastricht, NL-6229 ER Netherlands. Genmab, Utrecht, Netherlands. Hasselt Univ, Neuroimmunol Grp, Biomed Res Inst BIOMED, Diepenbeek, Belgium.-
local.type.refereedRefereed-
local.type.specifiedProceedings Paper-
local.relation.ispartofseriesnr1132-
dc.bibliographicCitation.oldjcatC1-
dc.identifier.doi10.1196/annals.1405.034-
dc.identifier.isi000257139900021-
local.bibliographicCitation.btitleMYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE-
item.contributorLosen, M-
item.contributorMartinez-Martinez, Pilar-
item.contributorPhernambucq, M-
item.contributorSchuurman, J-
item.contributorParren, PWWI-
item.contributorDE BAETS, Marc-
item.fullcitationLosen, M; Martinez-Martinez, Pilar; Phernambucq, M; Schuurman, J; Parren, PWWI & DE BAETS, Marc (2008) Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. In: Kaminski, HJ & Barohn, RJ (Ed.) MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE. p. 174-179..-
item.accessRightsClosed Access-
item.fulltextNo Fulltext-
item.validationecoom 2009-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.